Breast cancer, Cancer
OKUROnKure Therapeutics, Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for OKI-219 +/- Fulvestrant or Trastuzumab in Breast cancer, Cancer. The expected timing is based on the latest available company guidance and may change.
PIKture-01 Trial. 10/4/24- Merger w/ Reneo closed. 12/10/24- Reported prelim safety, PK and tolerability data. First patient dosing of combo portion w/ data in H2 2025. Present data at SABCS '24 on December 12, 2024. 03/12/26:- Updated Ph1 PIKture-01 Parts A/B and initial Part E data expected March 2026; Part C data in 2026. 05/05/26:- PIKture-01 enrollment complete; Ph2 dose evaluation completing 2026; independent OKI-219 development halted; final Ph1 data Q4 2026. 08/04/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.